Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Zanjan Pharmaceutical Biotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.
Int J Pharm. 2020 May 30;582:119320. doi: 10.1016/j.ijpharm.2020.119320. Epub 2020 Apr 9.
The application of nanoparticles (NPs) as radio-sensitizers and carriers has opened up a new horizon to overcome the limitations of chemo and radiotherapy. In this study, bovine serum albumin-coated BiS NPs (BiS@BSA NPs) were synthesized and evaluated in terms of their ability to be used as a radio-sensitizer and carrier for methotrexate (MTX). Physicochemical properties of MTX conjugated BiS@BSA NPs (BiS@BSA-MTX NPs) were characterized by DLS, TEM, FTIR, UV/Vis, and XRD analyses. After the evaluation of cellular uptake and intracellular localization, the cytotoxicity of the combination of BiS@BSA-MTX NPs and X-Ray radiation was analyzed against the SW480 cell line. The synthesized NPs exhibited spherical-like shapes and homogenous morphology, possessing a hydrodynamic diameter of 140.2 ± 5.71 nm (mean ± SD) and zeta potential of -25 mV. Also, the release study showed that the release of MTX is faster and higher in the presence of the proteinase K enzyme than the absence of the enzyme. The results of in-vitro chemo-radiation therapy indicated that the viability of treated cells with BiS@BSA-MTX NPs is significantly lower than the cells treated with BiS@BSA NPs. Furthermore, cells treated with BiS@BSA-MTX NPs showed a lower degree of viability when combined with X-Ray radiation in comparison with the absence of irradiation, which confirmed the ability of the BiS@BSA-MTX NPs as radio-sensitizer.
纳米粒子(NPs)作为放射增敏剂和载体的应用为克服化疗和放疗的局限性开辟了新的前景。在这项研究中,合成了牛血清白蛋白包覆的 BiS NPs(BiS@BSA NPs),并评估了其作为放射增敏剂和甲氨蝶呤(MTX)载体的能力。通过 DLS、TEM、FTIR、UV/Vis 和 XRD 分析对 MTX 共轭的 BiS@BSA NPs(BiS@BSA-MTX NPs)的物理化学性质进行了表征。在评估细胞摄取和细胞内定位后,分析了 BiS@BSA-MTX NPs 和 X 射线辐射联合对 SW480 细胞系的细胞毒性。合成的 NPs 呈现出球形形状和均匀的形态,具有 140.2±5.71nm(平均值±标准差)的水动力直径和-25mV 的 zeta 电位。此外,释放研究表明,在蛋白酶 K 酶存在的情况下,MTX 的释放速度更快,释放量更高。体外化疗放疗的结果表明,用 BiS@BSA-MTX NPs 处理的细胞活力明显低于用 BiS@BSA NPs 处理的细胞。此外,与没有辐照相比,用 BiS@BSA-MTX NPs 处理的细胞在与 X 射线联合辐照时的存活率更低,这证实了 BiS@BSA-MTX NPs 作为放射增敏剂的能力。